0.38% 0.0017

Handel nachbörslich: .46 0.014 +3.14%

Athira Pharma Inc (ATHA)

Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten

Athira Pharma Inc (ATHA)

Athira Pharma Inc Aktie (ATHA) Neueste Nachrichten

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by Forefront Analytics LLC - Defense World

Wall Street SWOT: Athira Pharma stock faces crossroads after Alzheimer's trial setback - Investing.com

Athira Pharma Inc (ATHA) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Athira Pharma stock plunges to 52-week low of $0.41 - Investing.com India

Athira Pharma stock plunges to 52-week low of $0.41 By Investing.com - Investing.com Canada

Taking a look at what insiders are doing to gauge the Athira Pharma Inc (ATHA)’s direction - Knox Daily

Check out these key findings about Athira Pharma Inc (ATHA) - SETE News

Was Athira Pharma Inc (ATHA)’s session last reading good? - US Post News

Athira Pharma to lay off 70% of workforce - PharmaLive

Athira Pharma Inc (ATHA) Becoming More Attractive for Investors - Knox Daily

Market Watch Highlights: Athira Pharma Inc (ATHA) Ends on an Downturn Note at 0.43 - The Dwinnex

Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com Canada

Athira Pharma stock faces pivot and workforce cuts amid trial setbackMizuho - Investing.com India

Athira Pharma Inc [ATHA] Officer makes an insider purchase of 5,032 shares worth 1.0. - Knox Daily

Athira Pharma stock hits 52-week low at $0.46 amid market challenges - Investing.com

Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 8.7% in August - Defense World

Taking the lead: Athira Pharma Inc (ATHA) - SETE News

Athira Pharma Inc Inc. (ATHA) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Athira Pharma Inc (NASDAQ: ATHA): Slumped -75.09% In 2024, Outlook Stable - Stocks Register

Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter

Athira Pharma lays off 70% of its staff as company shifts focus - The Business Journals

Athira Pharma to Cut About 70% of Workforce - MarketWatch

Athira Pharma to focus on ATH-1105 advancement, reduces workforce by 70% - TipRanks

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire

Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial - Being Patient

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewswire

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - StockTitan

Market Recap Check: Athira Pharma Inc (ATHA)’s Negative Finish at 0.51, Up/Down -4.18 - The Dwinnex

Is Athira Pharma Inc (ATHA) a opportunity to investors? - US Post News

Athira Pharma Inc [ATHA] Investment Guide: What You Need to Know - Knox Daily

Market Update: Athira Pharma Inc (ATHA) Sees Positive Movement, Closing at 0.51 - The Dwinnex

AdPha urges HTA reform - Pharmacy Daily

Fosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data - Alzheimer's News Today

Athira Pharma stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Australia

Ready to Jump After Recent Trade: Athira Pharma Inc (ATHA) - SETE News

Athira Pharma stock plunges to 52-week low of $0.46 - Investing.com

Rodman & Renshaw downgrades Athira Pharma Inc (ATHA) rating to a Neutral - Knox Daily

ATHA’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Recent Insider Activity Suggests Potential Gains for Athira Pharma Inc (ATHA) - Knox Daily

Closing Bell Recap: Athira Pharma Inc (ATHA) Ends at 0.54, Reflecting a -3.65 Downturn - The Dwinnex

StockWatch: Athira Pays Price as Alzheimer’s Candidate Fails Trial - Genetic Engineering & Biotechnology News

Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com Australia

Athira Pharma (ATHA) Stock Price, News & Analysis - MarketBeat

Athira Pharma COO Rachel Lenington sells shares worth $1,429 - Investing.com India

Athira plunges as Alzheimer’s trial setback leads to downgrades - MSN

Athira Pharma CEO sells over $2.8k in company stock - Investing.com

Athira Pharma COO Rachel Lenington sells shares worth $1,429 By Investing.com - Investing.com Canada

Athira Pharma executive sells shares on clinical trial milestone By Investing.com - Investing.com UK

Athira Pharma executive sells shares worth $1,429 By Investing.com - Investing.com UK

Athira Pharma tanks as fosgonimeton misses in Alzheimer’s trial | Pharmaceutical | The Pharmaletter - The Pharma Letter

Athira Pharma (NASDAQ:ATHA) Downgraded by BTIG Research to Neutral - Defense World

Athira Pharma (NASDAQ:ATHA) Downgraded to Neutral at Rodman & Renshaw - Defense World

Athira Pharma (NASDAQ:ATHA) Downgraded by JMP Securities to “Market Perform” - Defense World

Athira Pharma general counsel acquires shares, sells for $1.4k - Investing.com

Athira Pharma stock hits 52-week low at $0.7 amid market shifts - Investing.com

Athira Pharma stock hits 52-week low at $0.7 amid market shifts - Investing.com India

Athira’s Fosgonimeton Fails In Phase II/III LIFT-AD Trial, Future Uncertain - Scrip

Goldman Sachs moves Athira Pharma to Not Rated - TipRanks

Athira stock plunges on Alzheimer’s trial setback (NASDAQ:ATHA) - Seeking Alpha

Rodman & Renshaw Downgrades Athira Pharma (NASDAQ:ATHA) to Neutral - MarketBeat

Mizuho maintains Outperform rating on Athira Pharma shares despite trial miss - Investing.com Canada

Alzheimer’s Trial Failure Sends Athira Stock Down 75% - Barron's

Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Pharmaceutical Technology

Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Clinical Trials Arena

Athira’s stock topples after Alzheimer’s drug flops in Phase II/III trial - Yahoo Finance

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal - Yahoo Finance

Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks - AOL

Athira’s Small Molecule Injection for Alzheimer’s Flops in Phase II/III Study - BioSpace

Athira Pharma stock hits 52-week low at $0.7 amid market shifts - Investing.com UK

Why Is Athira Pharma Stock Plunging On Wednesday?Athira Pharma (NASDAQ:ATHA) - Benzinga

Athira Pharma tumbles after Alzheimer's drug fails trial - XM

Athira Pharma shares downgraded to neutral by BTIG - Investing.com

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial - ETHealthWorld

Athira Pharma downgraded to Neutral from Buy at BTIG - TipRanks

Stocks to Watch: Sportsman's Warehouse Holdings, PagerDuty, Athira Pharma - MarketWatch

Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial - STAT

Ähnlich wie ATHA